Companies / BOC Sciences / Ixekizumab
BOC Sciences

Ixekizumab | BOC Sciences

Ixekizumab is a humanized monoclonal antibody that inhibits interleukin 17A (IL-17A). It was approved by FDA for the treatment of moderate to severe plaque psoriasis in adult patients.

Reviews


No reviews yet

ABOUT THE COMPANY

BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.